Efficacy and safety of ezetimibe/simvastatin co-administered with fenofibrate in mixed hyperlipidemic patients with metabolic syndrome

Metabolic Syndrome and Related Disorders

Volumn 5, Issue 4, 2007, Pages 305-314

  Gil Extremera, Blas ^a   Mendez, Gustavo ^b   Zakson, Michelle ^b,c   Meehan, Alan ^b,c   Shah, Arvind ^b,c   Lin, Jianxin ^b,c   Mitchel, Yale ^b,c  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b Hospital de Especialidades No 14   (Mexico)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLECYSTOKININ BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 36749048664     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2007.0011     Document Type: Article

References (17)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001;285:2486-2497.
2. Vakkilainen J, Steiner G, Ansquer JC, Perttunen-Nìo H, Taskinen MR. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Diabetes Care 2002;25:627-628.
3. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-2134.
4. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79:620-629.
5. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004;26:1758-1773.
6. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am J Cardiol 2005;95:462-468.
7. McKenney JM, Farnier M, Lo KW, Bays H, Perevozskaya I, Carlson G et al. Safety and efficacy of long-term coadministration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47:1584-1587.
8. Farnier M, Freeman M, Macdonell G, Perevozskaya I, Davies M, Mitchel Y et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26:897-905.
9. Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, Hamlin C, Perevozskaya I, Davies MJ, Kush D, Mitchel YB, for the Ezetimibe/Simvastatin + Fenofibrate Study Group. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. American Heart Journal 2007:335.e1-e8.
10. Grundy SM, Cleeman JI, Merz CNB, Brewer Jr. HB, Clark LT, Hunninhake DB, Pasternak RC, Smith Jr. SC, Stone NJ, for the Coordinating Committee of the National Cholesterol Education Program. NCEP Report. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-239.
11. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97(2A):3A-11A.
12. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
13. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:426-462.
14. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum Creactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996;17:1345-1349.
15. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919-928.
16. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
17. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818.